This test identifies genetic insights that explain why you may be a poor responder to semaglutide alone and whether you'd benefit from tirzepatide, a dual GLP-1/GIP agonist, or a combination protocol instead
Indications and Usage for Imcivree IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged [ see Dosage and Administration (2.1)]: 4 years and older with acquired hypothalamic obesity (HO) 2 years and older with syndromic or monogenic obesity due to: o Bardet-Biedl syndrome (BBS) o Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)
Better Blood Sugar Control GLP-1 agonists prompt the pancreas to release insulin when blood sugar rises and help limit excess glucose
At most, one might eventually acknowledge that they feel better compared to an earlier state, but that isnt like seeing a lower weight on the bathroom scale or noticing increases in sustained cognitive effort
For complete prescribing information, please refer to the package insert available here
Move administration earlier if you currently take it close to your first meal
